List view / Grid view




Time to renew the antibiotic arsenal

19 January 2016 | By Philippe Villain-Guillot, CEO, Nosopharm

Philippe Villain-Guillot, CEO, Nosopharm, discusses antimicrobial resistance and the challenges facing antibacterial drug discovery and development...


Nosopharm joins ENABLE to help combat antibiotic resistance

7 December 2015 | By Victoria White

The €100m ENABLE project aims to identify at least three antibacterial lead molecules with promising antibacterial activity, two antibacterial clinical candidate molecules and to enter at least one compound into preclinical and Phase 1 clinical studies...